U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07294170) titled 'ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis' on Dec. 08.
Brief Summary: ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life.
Study Start Date: Dec., 2025
Study Type: OBSERVATIONAL
Condition:
Myasthenia Gravis
MG
gMG
Generalized Myasthenia Gravis
Generalized Myasthenia Gravis (gMG)
AChR-Ab Seropositive Generalized Myasthe...